Elicio Therapeutics, Inc. ELTX
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is an oncology drug developer. Its lead program, ELI-002 7P, is in Phase 2 for Adjuvant mKRAS-driven pancreatic ductal adenocarcinoma (PDAC). Its next catalyst on record is ELI-002 7P + RAS inhibitor +/- anti-PD-1: Initiation of Phase 1 study in metastatic PDAC (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: ELI-002 7P + RAS inhibitor +/- anti-PD-1 — Initiation of Phase 1 study in metastatic PDAC (Q4 2026). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ELI-002 7P | Adjuvant mKRAS PDAC (Phase 2 AMPLIFY-7P completed, missed primary DFS endpoint; Phase 3 planned subject to financing) | vaccine | Phase 2 |
| ELI-002 2P | mKRAS solid tumors / CRC (Phase 1 AMPLIFY-201 completed) | vaccine | Phase 1 |
| ELI-002 7P + RAS inhibitor +/- anti-PD-1 | Metastatic mKRAS PDAC | vaccine | Pre-clinical |
| ELI-007 | BRAF-driven cancers | vaccine | Pre-clinical |
| ELI-008 | TP53-mutated cancers | vaccine | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
- Tango Therapeutics, Inc. TNGX
- Tyra Biosciences, Inc. TYRA
- Verastem, Inc. VSTM
- Obsidian Therapeutics, Inc. OBX
- Puma Biotechnology, Inc. PBYI
- Fulgent Genetics, Inc. FLGT
- Delcath Systems, Inc. DCTH
- Unknown Unknown
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.